• Diagnosis​ ​Info​ ​and​ ​General​ ​Questions

  Phase 2 CF Trial Testing SPI-1005 for Ototoxicity Proceeds

  Posted by cystic-fibrosis-news-moderator on January 22, 2019 at 6:43 pm

  Sound Pharmaceuticals (SPI) has enrolled its first-patient-in — meaning the first subject meeting the criteria for inclusion and exclusion of a clinical study — in a Phase 2 trial testing SPI-1005 for the prevention and treatment of tobramycin-induced ototoxicity in cystic fibrosis (CF) patients, the company announced. Click here to read more about this trial.

  Would you like to follow news about this trial?

  cystic-fibrosis-news-moderator replied 5 years, 3 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply